COVID-19 and Hypertension

Introduction

Infection with SARS-CoV-2 is the causative agent of coronavirus disease 2019 (COVID-19), which the WHO has described as a pandemic. As of July 27th, 2020, this disease has killed more than 16.3 million people worldwide and it appears that underlying cardiovascular disease constitutes substantial comorbidity correlated with the clinical decline and adverse outcomes in COVID-19 patients. Preliminary reports stated that hypertension may be associated with increased risk of SARS-CoV-2 infection but it now appears that older age and hypertension-related comorbidities somewhat confound this relationship. However, following the initial findings of using RAAS blockers with a higher risk of SARS-CoV-2 infection and a more serious course of COVID-19, it is now recognized that no solid scientific results are available in humans to support them. The application of RAAS blockers care in patients with appropriate indications are widely recommended by major international research organizations.

Discussion

Several reports of unexplained pneumonia, on December 2019 the world’s Etiology was reported in Wuhan, Hubei province, China, World Health Organization [1] and Huan Seafood was linked to wholesale [2]. The virus responsible for the outbreak A coronavirus called Extreme Acute Respiratory was of pneumonia Coronavirus-2 syndrome (SARS-CoV-2), and COVID-19 The name was given to the associated disease was Disease which the WHO has officially recognized as a global disease Pandemic of March, 2020. As of 27 July 2020, COVID-19 has infected a total of 16,535,494 people, almost one-fourth of who live in the United States and killed nearly 654,081 people worldwide. Though 10,127,507 have recovered so far, global healthcare systems continue to be burdened with 66,404 million active cases, millions of people which are in Serious life-threatening conditions and a large share of them suffer From other comorbidities, such as elevated blood pressure, diabetes mellitus or Cardiovascular infections [3].

With regard to viral transmission, SARS-CoV-2 is considered to be contained in respiratory droplets, though airborne discharge virus is not yet known. In addition to this, SARS-CoV-2 was known in other body fluids, including blood, saliva, cerebrospinal tract Fluid, urine, and tears, but it is not yet known whether they can be passed on through these biological materials [4]. SARS-CoV distribution-2 However, this is deemed feasible via the fecal-oral route has not yet been confirmed. Patients diagnosed with SARS-CoV-2 could have unspecific presence symptoms and others may even be asymptomatic before they arise Effective Test.

The incubation time normally ranges from 1 to 14 days but people with symptoms often affected about the five-day post-infection period. The Clinical Cardinal COVID-19 types mimic that of viral pneumonia. Hard Cases require the occurrence of non-specific symptoms, for example, tiredness, nausea, malaise, headache, dry or active cough, Anorexia, sore throat, and shortness of breath. In certain instances, it can also affect the gastrointestinal tract. In serious cases of COVID-19, they typically manifest as extreme pneumonia and are often followed by lethal complications, such as acute respiratory distress syndrome, septic shock, or acute kidney complications. An injury that results in kidney failure [5].

In total, almost 80 percent of patients have mild symptoms, whilst around 14% have severe symptoms for the disease and almost 5% are considered seriously ill. The elderly population is more vulnerable to infection compared to the younger ones and the extreme form of the disease occurs mainly in elderly men [6]. This should also be noted that older patients are there are
both comorbidities and immune-compromised topics increased risk of degradation even after their initial clinical presentation is gentle. Such specific patients may also frequently have atypical conditions Clinical features; thereby further perplexing on-time diagnosis of COVID-19.

In keeping with the latest facts, RAAS for the moment in the current scenario, blockers seem fairer than harmful Era COVID-19. The abolition of RAAS blockers in patients having already obtained them would most likely result in a higher rate of Cardiovascular and mortal complications. The School of America of The Cardiology/American Heart Failure Society America, the Board of the American Society of Hypertension Cardiology, and the Cardiovascular Society of Canada both published their Legal statements of position concerning the use of ACEi/ARB medicines COVID-19 for heart failure and/or hypertension patients.

References
1. World Health Organization (WHO). Coronavirus disease (COVID-19) outbreak.
2. World Health Organisation Pneumonia of unknown cause-China. (2020).
3. Worldometer. Covid-19 coronavirus pandemic.
4. Jun IS, Anderson DE, Kang AE, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmol. 127(7): 977-979 (2020).
5. WHO. Report of the WHO-China Joint Mission. (2020).
6. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China. 2(8): 113-122 (2020).